Determining EBV load: current best practice and future requirements

References

• Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 9(3), 395–404 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen JI. Epstein–Barr virus infection. N. Engl. J. Med. 343(7), 481–492 (2000).
   PubMed Web of Science ®Google Scholar
• Hsu JL, Glaser SL. Epstein–Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit. Rev. Oncol. Hematol. 34(1), 27–53 (2000).
   PubMed Web of Science ®Google Scholar
• Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein–Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev. Med. Virol. 18(5), 305–319 (2008).
   PubMed Web of Science ®Google Scholar
• Gulley ML, Tang W. Using Epstein–Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23(2), 350–366 (2010).
   PubMed Web of Science ®Google Scholar
• Fryer JF, Heath AB, Wilkinson DE, Minor PD. Collaborative study to evaluate the proposed 1st WHO International Standard for Epstein–Barr virus (EBV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report. (2011).
   Google Scholar
• Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein–Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J. Mol. Diagn. 6(4), 378–385 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am. J. Transplant. 8(5), 1016–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 6(10), 986–994 (1996).
   PubMed Web of Science ®Google Scholar
• Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. J. Clin. Microbiol. 37(1), 132–136 (1999).
   PubMed Web of Science ®Google Scholar
• Espy MJ, Uhl JR, Sloan LM et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin. Microbiol. Rev. 19(1), 165–256 (2006).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verkuijlen SA, Hariwiyanto B et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein–Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int. J. Cancer 119(3), 608–614 (2006).
   PubMed Web of Science ®Google Scholar
• Hayden RT, Hokanson KM, Pounds SB et al.; U.S. EBV Working Group. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein–Barr virus. J. Clin. Microbiol. 46(1), 157–163 (2008).
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG; American Society of Transplantation Infectious Diseases Community of Practice. Interlaboratory comparison of Epstein–Barr virus viral load assays. Am. J. Transplant. 9(2), 269–279 (2009).
   PubMed Web of Science ®Google Scholar
• Le QT, Jones CD, Yau TK et al. A comparison study of different PCR assays in measuring circulating plasma Epstein–Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin. Cancer Res. 11(16), 5700–5707 (2005).
   PubMed Web of Science ®Google Scholar
• Ishii H, Ogino T, Berger C et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for nasal NK/T-cell lymphoma. J. Med. Virol. 79(5), 562–572 (2007).
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350(13), 1328–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Rowe M, Niedobitek G, Young LS. Epstein–Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Semin. Immunopathol. 20(3–4), 389–403 (1998).
   PubMed Web of Science ®Google Scholar
• Roughan JE, Torgbor C, Thorley-Lawson DA. Germinal center B cells latently infected with Epstein–Barr virus proliferate extensively but do not increase in number. J. Virol. 84(2), 1158–1168 (2010).
   PubMed Web of Science ®Google Scholar
• Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein–Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190(4), 567–576 (1999).
   PubMed Web of Science ®Google Scholar
• Ambinder RF, Lin L. Mononucleosis in the laboratory. J. Infect. Dis. 192(9), 1503–1504 (2005).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kimura H, Hironaka T et al. Detection and quantification of virus DNA in plasma of patients with Epstein–Barr virus-associated diseases. J. Clin. Microbiol. 33(7), 1765–1768 (1995).
   PubMed Web of Science ®Google Scholar
• Fafi-Kremer S, Morand P, Brion JP et al. Long-term shedding of infectious Epstein–Barr virus after infectious mononucleosis. J. Infect. Dis. 191(6), 985–989 (2005).
   PubMed Web of Science ®Google Scholar
• Bauer CC, Aberle SW, Popow-Kraupp T, Kapitan M, Hofmann H, Puchhammer‑Stöckl E. Serum Epstein–Barr virus DNA load in primary Epstein–Barr virus infection. J. Med. Virol. 75(1), 54–58 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72(6), 1012–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. Dynamics of Epstein–Barr virus DNA levels in serum during EBV-associated disease. J. Med. Virol. 64(4), 505–512 (2001).
   PubMed Web of Science ®Google Scholar
• Brengel-Pesce K, Morand P, Schmuck A et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein–Barr virus infections. J. Med. Virol. 66(3), 360–369 (2002).
   PubMed Web of Science ®Google Scholar
• Ryan JL, Fan H, Swinnen LJ et al. Epstein–Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn. Mol. Pathol. 13(2), 61–68 (2004).
   PubMed Web of Science ®Google Scholar
• Berth M, Vanheule G, Depuydt C, Benoy I. Serum Epstein–Barr virus (EBV) viral load can be a complementary sensitive test in primary Epstein–Barr virus infection. J. Clin. Virol. 50(2), 184–185 (2011).
   PubMed Web of Science ®Google Scholar
• Meerbach A, Gruhn B, Egerer R, Reischl U, Zintl F, Wutzler P. Semiquantitative PCR analysis of Epstein–Barr virus DNA in clinical samples of patients with EBV-associated diseases. J. Med. Virol. 65(2), 348–357 (2001).
   PubMed Web of Science ®Google Scholar
• Maurmann S, Fricke L, Wagner HJ et al. Molecular parameters for precise diagnosis of asymptomatic Epstein–Barr virus reactivation in healthy carriers. J. Clin. Microbiol. 41(12), 5419–5428 (2003).
   PubMed Web of Science ®Google Scholar
• Balfour HH Jr, Holman CJ, Hokanson KM et al. A prospective clinical study of Epstein–Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis. 192(9), 1505–1512 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood 118(15), 4041–4052 (2011).
   PubMed Web of Science ®Google Scholar
• Kimura H, Nishikawa K, Hoshino Y, Sofue A, Nishiyama Y, Morishima T. Monitoring of cell-free viral DNA in primary Epstein–Barr virus infection. Med. Microbiol. Immunol. 188(4), 197–202 (2000).
   PubMed Web of Science ®Google Scholar
• Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ. Infection of T lymphocytes in Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr. Blood Cancer 53(2), 184–190 (2009).
   PubMed Web of Science ®Google Scholar
• Teramura T, Tabata Y, Yagi T, Morimoto A, Hibi S, Imashuku S. Quantitative analysis of cell-free Epstein–Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk. Lymphoma 43(1), 173–179 (2002).
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kimura H, Yoshino T et al.; CAEBV Study Group. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol. Int. 58(4), 209–217 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein–Barr virus infection. Blood 98(2), 280–286 (2001).
   PubMed Web of Science ®Google Scholar
• Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Miyawaki T, Tosato G. Increased cell-free viral DNA in fatal cases of chronic active Epstein–Barr virus infection. Clin. Infect. Dis. 28(4), 906–909 (1999).
   PubMed Web of Science ®Google Scholar
• Gotoh K, Ito Y, Shibata-Watanabe Y et al. Clinical and virological characteristics of 15 patients with chronic active Epstein–Barr virus infection treated with hematopoietic stem cell transplantation. Clin. Infect. Dis. 46(10), 1525–1534 (2008).
   PubMed Web of Science ®Google Scholar
• Chan KC, Zhang J, Chan AT et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 63(9), 2028–2032 (2003).
   PubMed Web of Science ®Google Scholar
• To EW, Chan KC, Leung SF et al. Rapid clearance of plasma Epstein–Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9(9), 3254–3259 (2003).
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan AT, Chan LY et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein–Barr virus DNA. Cancer Res. 60(24), 6878–6881 (2000).
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350(24), 2461–2470 (2004).
   PubMed Web of Science ®Google Scholar
• Chan AT, Lo YM, Zee B et al. Plasma Epstein–Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl. Cancer Inst. 94(21), 1614–1619 (2002).
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan LY, Chan AT et al. Quantitative and temporal correlation between circulating cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59(21), 5452–5455 (1999).
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1), 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein–Barr virus DNA in natural killer/T-cell lymphoma. Clin. Cancer Res. 8(1), 29–34 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K et al.; NK-cell Tumor Study Group. Prospective measurement of Epstein–Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 118(23), 6018–6022 (2011).
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim KH, Kim KH et al. Whole blood Epstein–Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk. Lymphoma 50(5), 757–763 (2009).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST; Asian Oncology Summit. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10(11), 1093–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Dearden CE, Johnson R, Pettengell R et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br. J. Haematol. 153(4), 451–485 (2011).
   PubMed Web of Science ®Google Scholar
• Gärtner B, Preiksaitis JK. EBV viral load detection in clinical virology. J. Clin. Virol. 48(2), 82–90 (2010).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Burrows J et al. Plasma Epstein–Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin. Cancer Res. 12(2), 460–464 (2006).
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein–Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br. J. Haematol. 111(1), 239–246 (2000).
   PubMed Web of Science ®Google Scholar
• Gallagher A, Armstrong AA, MacKenzie J et al. Detection of Epstein–Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int. J. Cancer 84(4), 442–448 (1999).
   PubMed Web of Science ®Google Scholar
• Spacek M, Hubacek P, Markova J et al. Plasma EBV-DNA monitoring in Epstein–Barr virus-positive Hodgkin lymphoma patients. APMIS 119(1), 10–16 (2011).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Schläger F, Claviez A, Bucsky P. Detection of Epstein–Barr virus DNA in peripheral blood of paediatric patients with Hodgkin’s disease by real-time polymerase chain reaction. Eur. J. Cancer 37(15), 1853–1857 (2001).
   PubMed Web of Science ®Google Scholar
• Solassol J, Kreuzer KA, Lass U, Schmidt CA. Epstein–Barr virus DNA quantitation assessed by a real-time polymerase chain reaction in a case of Burkitt’s lymphoma. Leuk. Lymphoma 41(5–6), 669–673 (2001).
   PubMed Web of Science ®Google Scholar
• Machado AS, Da Silva Robaina MC, Magalhães De Rezende LM et al. Circulating cell-free and Epstein–Barr virus DNA in pediatric B-non-Hodgkin lymphomas. Leuk. Lymphoma 51(6), 1020–1027 (2010).
   PubMed Web of Science ®Google Scholar
• Jo SA, Hwang SH, Kim SY et al. Quantitation of whole blood Epstein–Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin’s lymphoma. Int. J. Lab. Hematol. 32(1 Pt 1), e106–e113 (2010).
   PubMed Web of Science ®Google Scholar
• Ma SD, Hegde S, Young KH et al. A new model of Epstein–Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85(1), 165–177 (2011).
   PubMed Web of Science ®Google Scholar
• Kitai R, Matsuda K, Adachi E et al. Epstein–Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol. Med. Chir. (Tokyo) 50(2), 114–118 (2010).
   PubMed Web of Science ®Google Scholar
• Sugita Y, Terasaki M, Niino D et al. Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J. Neurooncol. 100(2), 271–279 (2010).
   PubMed Web of Science ®Google Scholar
• Chen JN, He D, Tang F, Shao CK. Epstein–Barr virus-associated gastric carcinoma: a newly defined entity. J. Clin. Gastroenterol. 46(4), 262–271 (2012).
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan WY, Ng EK et al. Circulating Epstein–Barr virus DNA in the serum of patients with gastric carcinoma. Clin. Cancer Res. 7(7), 1856–1859 (2001).
   PubMed Web of Science ®Google Scholar
• Chen MR. Epstein–Barr virus, the immune system, and associated diseases. Front. Microbiol. 2, 5 (2011).
   PubMed Web of Science ®Google Scholar
• Hon GM, Hassan MS, van Rensburg SJ, Erasmus RT, Matsha TE. Assessment of Epstein–Barr virus in blood from patients with multiple sclerosis. Metab. Brain Dis. 27(3), 311–318 (2012).
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94(7), 2208–2216 (1999).
   PubMed Web of Science ®Google Scholar
• Parker A, Bowles K, Bradley JA et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. Br. J. Haematol. 149(5), 693–705 (2010).
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H et al.; Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 43(10), 757–770 (2009).
   PubMed Web of Science ®Google Scholar
• Allen U, Preiksaitis J and the AST Infectious Diseases Community of Practice. Epstein–Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S87–96 (2009).
   PubMed Web of Science ®Google Scholar
• Ahya VN, Douglas LP, Andreadis C et al. Association between elevated whole blood Epstein–Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J. Heart Lung Transplant. 26(8), 839–844 (2007).
   PubMed Web of Science ®Google Scholar
• Doesch AO, Konstandin M, Celik S et al. Epstein–Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transpl. Int. 21(10), 963–971 (2008).
   PubMed Web of Science ®Google Scholar
• Bakker NA, Verschuuren EA, Veeger NJ et al. Quantification of Epstein–Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood. J. Heart Lung Transplant. 27(1), 7–10 (2008).
   PubMed Web of Science ®Google Scholar
• Green M, Cacciarelli TV, Mazariegos GV et al. Serial measurement of Epstein–Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 66(12), 1641–1644 (1998).
   PubMed Web of Science ®Google Scholar
• Jabs WJ, Maurmann S, Wagner HJ, Müller-Steinhardt M, Steinhoff J, Fricke L. Time course and frequency of Epstein–Barr virus reactivation after kidney transplantation: linkage to renal allograft rejection. J. Infect. Dis. 190(9), 1600–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein–Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 74(5), 656–664 (2002).
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der Holt B, Meijer E et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT. Blood 98(4), 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Yang J, Tao Q, Flinn IW et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96(13), 4055–4063 (2000).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103(10), 3979–3981 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmad I, Cau NV, Kwan J et al. Preemptive management of Epstein–Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 87(8), 1240–1245 (2009).
   PubMed Web of Science ®Google Scholar
• Coppoletta S, Tedone E, Galano B et al. Rituximab treatment for Epstein–Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 17(6), 901–907 (2011).
   PubMed Web of Science ®Google Scholar
• Oertel S, Trappe RU, Zeidler K et al. Epstein–Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann. Hematol. 85(7), 478–484 (2006).
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 7(6), 1648–1655 (2007).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5), 1549–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108(9), 2942–2949 (2006).
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a Phase 2 multicenter clinical trial. Blood 110(4), 1123–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Ambinder RF. Hiding in plain sight. Blood 108(9), 2891 (2006).
   Web of Science ®Google Scholar
• Bingler MA, Feingold B, Miller SA et al. Chronic high Epstein–Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am. J. Transplant. 8(2), 442–445 (2008).
   PubMed Web of Science ®Google Scholar
• Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein–Barr viral load carriage in pediatric liver transplant recipients. Pediatr. Transplant. 13(3), 319–323 (2009).
   PubMed Web of Science ®Google Scholar
• Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M. Chronic high Epstein–Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr. Transplant. 14(4), 549–553 (2010).
   PubMed Web of Science ®Google Scholar
• Tanaka E, Sato T, Ishihara M et al. Asymptomatic high Epstein–Barr viral load carriage in pediatric renal transplant recipients. Pediatr. Transplant. 15(3), 306–313 (2011).
   PubMed Web of Science ®Google Scholar
• Ruf S, Behnke-Hall K, Gruhn B et al. Comparison of six different specimen types for Epstein–Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J. Clin. Virol. 53(3), 186–194 (2012).
   PubMed Web of Science ®Google Scholar
• Kullberg-Lindh C, Olofsson S, Brune M, Lindh M. Comparison of serum and whole blood levels of cytomegalovirus and Epstein–Barr virus DNA. Transpl. Infect. Dis. 10(5), 308–315 (2008).
   PubMed Web of Science ®Google Scholar
• Ishihara M, Tanaka E, Sato T et al. Epstein–Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Clin. Nephrol. 76(1), 40–48 (2011).
   PubMed Web of Science ®Google Scholar
• Hakim H, Gibson C, Pan J et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein–Barr virus in peripheral blood. J. Clin. Microbiol. 45(7), 2151–2155 (2007).
   PubMed Web of Science ®Google Scholar
• Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand. J. Infect. Dis. 39(3), 235–244 (2007).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J. Clin. Microbiol. 39(4), 1211–1216 (2001).
   PubMed Web of Science ®Google Scholar
• Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein–Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79(22), 13993–14003 (2005).
   PubMed Web of Science ®Google Scholar
• Smets F, Latinne D, Bazin H et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73(10), 1603–1610 (2002).
   PubMed Web of Science ®Google Scholar
• Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein–Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101(11), 4290–4297 (2003).
   PubMed Web of Science ®Google Scholar
• Clave E, Agbalika F, Bajzik V et al. Epstein–Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 77(1), 76–84 (2004).
   PubMed Web of Science ®Google Scholar
• Sebelin-Wulf K, Nguyen TD, Oertel S et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl. Immunol. 17(3), 203–210 (2007).
   PubMed Web of Science ®Google Scholar
• Sato T, Fujieda M, Maeda A et al. Monitoring of Epstein–Barr virus load and killer T cells in pediatric renal transplant recipients. Clin. Nephrol. 70(5), 393–403 (2008).
   PubMed Web of Science ®Google Scholar
• D’Aveni M, Aïssi-Rothé L, Venard V et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 24(4), 224–232 (2011).
   PubMed Web of Science ®Google Scholar
• Worth A, Conyers R, Cohen J et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein–Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br. J. Haematol. 155(3), 377–385 (2011).
   PubMed Web of Science ®Google Scholar
• Macedo C, Webber SA, Donnenberg AD et al. EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J. Immunol. 186(10), 5854–5862 (2011).
   PubMed Web of Science ®Google Scholar
• Gotoh K, Ito Y, Ohta R et al. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein–Barr virus loads. J. Infect. Dis. 202(3), 461–469 (2010).
   PubMed Web of Science ®Google Scholar
• Moran J, Carr M, Waters A et al. Epstein–Barr virus gene expression, human leukocyte antigen alleles and chronic high viral loads in pediatric renal transplant patients. Transplantation 92(3), 328–333 (2011).
   PubMed Web of Science ®Google Scholar
• Fan H, Kim SC, Chima CO et al. Epstein–Barr viral load as a marker of lymphoma in AIDS patients. J. Med. Virol. 75(1), 59–69 (2005).
   PubMed Web of Science ®Google Scholar
• Leruez-Ville M, Seng R, Morand P et al. Blood Epstein–Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma. HIV Med. 13(8), 479–487 (2012).
   PubMed Web of Science ®Google Scholar
• Bonnet F, Jouvencel AC, Parrens M et al. A longitudinal and prospective study of Epstein–Barr virus load in AIDS-related non-Hodgkin lymphoma. J. Clin. Virol. 36(4), 258–263 (2006).
   PubMed Web of Science ®Google Scholar
• Tedeschi R, Bortolin MT, Bidoli E et al. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. J. Clin. Virol. 53(4), 297–301 (2012).
   PubMed Web of Science ®Google Scholar
• Van Baarle D, Wolthers KC, Hovenkamp E et al. Absolute level of Epstein–Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J. Infect. Dis. 186(3), 405–409 (2002).
   PubMed Web of Science ®Google Scholar
• Fellner MD, Durand K, Correa RM et al. Circulating Epstein–Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int. J. Infect. Dis. 11(2), 172–178 (2007).
   PubMed Web of Science ®Google Scholar
• Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein–Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin. Infect. Dis. 38(11), 1629–1632 (2004).
   PubMed Web of Science ®Google Scholar
• Bower M, Collins S, Cottrill C et al.; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 9(6), 336–388 (2008).
   PubMed Web of Science ®Google Scholar
• Antinori A, De Rossi G, Ammassari A et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein–Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J. Clin. Oncol. 17(2), 554–560 (1999).
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, De Luca A et al. Epstein–Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Ann. Neurol. 45(2), 259–261 (1999).
   PubMed Web of Science ®Google Scholar
• Wang J, Ozzard A, Nathan M et al. The significance of Epstein–Barr virus detected in the cerebrospinal fluid of people with HIV infection. HIV Med. 8(5), 306–311 (2007).
   PubMed Web of Science ®Google Scholar
• Jonigk D, Laenger F, Maegel L et al. Molecular and clinicopathological analysis of Epstein–Barr virus-associated posttransplant smooth muscle tumors. Am. J. Transplant. 12(7), 1908–1917 (2012).
   PubMed Web of Science ®Google Scholar
• Jenson HB, Leach CT, McClain KL et al. Benign and malignant smooth muscle tumors containing Epstein–Barr virus in children with AIDS. Leuk. Lymphoma 27(3-4), 303–314 (1997).
   PubMed Web of Science ®Google Scholar
• Suankratay C, Shuangshoti S, Mutirangura A et al. Epstein–Barr virus infection-associated smooth-muscle tumors in patients with AIDS. Clin. Infect. Dis. 40(10), 1521–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Filipovich A, Johnson J, Zhang K, Marsh R. Lymphoproliferative disease, X-linked. In: GeneReviews™. Pagon RA (Ed.). University of Washington, WA, USA (2011).
   Google Scholar
• Ito Y, Takakura S, Ichiyama S et al. Multicenter evaluation of prototype real-time PCR assays for Epstein–Barr virus and cytomegalovirus DNA in whole blood samples from transplant recipients. Microbiol. Immunol. 54(9), 516–522 (2010).
   PubMed Web of Science ®Google Scholar
• Abbate I, Zanchetta M, Gatti M et al. Multicenter comparative study of Epstein–Barr virus DNA quantification for virological monitoring in transplanted patients. J. Clin. Virol. 50(3), 224–229 (2011).
   PubMed Web of Science ®Google Scholar
• Hayden RT, Yan X, Wick MT et al.; College of American Pathologists Microbiology Resource Committee. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J. Clin. Microbiol. 50(2), 337–345 (2012).
   PubMed Web of Science ®Google Scholar
• Allan GJ, Rowe DT. Size and stability of the Epstein–Barr virus major internal repeat (IR-1) in Burkitt’s lymphoma and lymphoblastoid cell lines. Virology 173(2), 489–498 (1989).
   PubMed Web of Science ®Google Scholar
• Tierney RJ, Kao KY, Nagra JK, Rickinson AB. Epstein–Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J. Virol. 85(23), 12362–12375 (2011).
   PubMed Web of Science ®Google Scholar
• White RA 3rd, Quake SR, Curr K. Digital PCR provides absolute quantitation of viral load for an occult RNA virus. J. Virol. Methods 179(1), 45–50 (2012).
   PubMed Web of Science ®Google Scholar
• Annels NE, Kalpoe JS, Bredius RG et al. Management of Epstein–Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin. Infect. Dis. 42(12), 1743–1748 (2006).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97(5), 1165–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Baldanti F, Gatti M, Furione M et al. Kinetics of Epstein–Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J. Clin. Microbiol. 46(11), 3672–3677 (2008).
   PubMed Web of Science ®Google Scholar
• Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am. J. Transplant. 5(9), 2222–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. Monitoring of Epstein–Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J. Med. Virol. 80(3), 441–454 (2008).
   PubMed Web of Science ®Google Scholar
• Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein–Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84(3), 972–984 (1994).
   PubMed Web of Science ®Google Scholar
• Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein–Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60(6), 547–554 (1995).
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Kimura H, Tanaka N et al. Prospective monitoring of the Epstein–Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br. J. Haematol. 115(1), 105–111 (2001).
   PubMed Web of Science ®Google Scholar